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of all-cause mortality in each patient and this risk was com-
pared with the observed 2-year mortality. Discrimination 
and calibration were assessed as well as the strength of as-
sociation between the 15-point ADO score and the ob-
served 2-year all-cause mortality.  Results: Fifty-two (8.1%) 
patients died during the 2-year follow-up period. Discrimi-
nation with the ADO index was excellent with an area under 
the curve of 0.78 [95% confidence interval (CI) 0.71–0.84]. 
Overall, the predicted and observed risks matched well and 
visual inspection revealed no important differences be-
tween them across 10 risk classes (p = 0.68). The odds ratio 
for death per point increase according to the ADO index was 
1.50 (95% CI 1.31–1.71).  Conclusions: The ADO index 
showed excellent prediction properties in an out-of-popu-
lation validation carried out in COPD patients from primary 
care settings.  © 2014 S. Karger AG, Basel 
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 Abstract 
 Background: Existing prediction models for mortality in 
chronic obstructive pulmonary disease (COPD) patients 
have not yet been validated in primary care, which is where 
the majority of patients receive care.  Objectives: Our aim 
was to validate the ADO (age, dyspnoea, airflow obstruc-
tion) index as a predictor of 2-year mortality in 2 general 
practice-based COPD cohorts.  Methods: Six hundred and 
forty-six patients with COPD with GOLD (Global Initiative for 
Chronic Obstructive Lung Disease) stages I–IV were enrolled 
by their general practitioners and followed for 2 years. The 
ADO regression equation was used to predict a 2-year risk 
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 Introduction 
 Chronic obstructive pulmonary disease (COPD) is 
one of the leading causes of mortality worldwide and is 
therefore a major public health concern. With its preva-
lence rising, the WHO estimation is that it will be the 
third leading cause of death by 2030  [1, 2] . Many multi-
dimensional indices like BODE (body mass index, airflow 
obstruction, dyspnoea and exercise capacity), DOSE 
(dyspnoea, obstruction, smoking and exacerbation) and 
ADO (age, dyspnoea and airflow obstruction) have been 
developed to predict mortality in COPD  [3–5] .
 In 2009, Puhan et al.  [5] recalibrated and updated the 
BODE index in 2 separate European COPD cohorts. 
They recognised that the reduced distance in the 6-min-
ute-walk-test had an even greater impact on mortality 
than in the original cohort in the USA. They also ob-
served that age, dyspnoea and FEV 1 had a strong asso-
ciation with 3-year mortality and that these parameters 
could be used as predictors for mortality  [5] . The new 
index was called the ADO index. It has the clear advan-
tage that 6-minute-walk-test data are not required; it is 
often not practicable to perform this test in a general 
practice setting, so the ADO is more convenient than the 
BODE index. In a recent, large-scale validation in almost 
14,000 patients with COPD from diverse settings, the 
ADO showed good predictive performance after updat-
ing the underlying regression equation (intercept and 
coefficients)  [6] . However, ADO has not been investi-
gated in purely general practice-based cohorts. Neither 
has its ability to predict mortality in a shorter time been 
assessed. Our aim was to assess the performance of the 
ADO index in predicting 2-year mortality in 2 general 
practice-based COPD cohorts, in Switzerland and the 
Netherlands.
 Material and Methods 
 Study Design and Patients 
 Data from 2 general practice-based COPD cohorts, namely the 
Swiss COPD Cohort and the International Collaborative Effort on 
Chronic Obstructive Lung Disease: Exacerbation Risk Index Co-
horts (ICE COLD ERIC) were pooled  [7–10] .
 Swiss COPD Cohort Study 
 General practitioners (GPs) from all over Switzerland were in-
vited to participate in the study; 139 agreed to participate and each 
recruited 1–20 patients ( ≥ 40 years of age) with presumed mild to 
very severe COPD according to the criteria of the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD). The exclusion cri-
teria were dementia or psychiatric morbidity and an inability to 
complete the questionnaires due to language difficulties  [11, 12] . 
Each patient underwent a baseline assessment (demographic data, 
physical examination, spirometric parameters, medical treatment 
and exacerbation history) and was then followed for 24 months. 
Data were entered into a central online database either by the phy-
sicians or by the study team after receiving the collected data ques-
tionnaires by facsimile. The ethics committees of each canton with 
participating GPs approved the study protocol and all patients 
provided their written informed consent. For more details on this 
cohort, we referred to earlier publications  [7, 8] . We used data 
from 2007 to 2010 for this study.
 ICE COLD ERIC Study 
 In this ongoing, prospective, multi-centre cohort study, COPD 
patients from primary care were enrolled in the Netherlands and 
in Switzerland between April 2008 and August 2009  [9, 10] . At 
inclusion, all patients ( ≥ 40 years of age) had GOLD stage II–IV 
COPD and had been free of exacerbations for  ≥ 4 weeks. The only 
exclusion criteria were a life expectancy of <12 months and de-
mentia or psychotic morbidity. All patients provided their written 
informed consent. After a comprehensive baseline assessment, 
they were followed up every 6 months for up to 5 years. All data, 
in duplicate, were entered centrally into a database managed by 
the Clinical Research Unit of the Academic Medical Center Am-
sterdam, The Netherlands. The study was approved by all local 
ethics committees and is registered on ClinicalTrials.gov 
(NCT00706602). Detailed information about the study protocol 
and results are available elsewhere  [9, 10] . None of the patients 
from the Swiss COPD cohort were included in the Swiss arm of 
this cohort.
 Measurement of Predictors and Mortality 
 In both studies, age was recorded at baseline and all patients 
completed the modified Medical Research Council (mMRC) dys-
pnoea scale  [13, 14] . Spirometry was performed according to the 
2005 guidelines of the American Thoracic Society  [15] .  A spirom-
eter (EasyOne TM , ndd Medizintechnik AG, Zürich, Switzerland) 
was used in both studies to assess lung function as described pre-
viously  [7, 8, 10] . All participating physicians were instructed on 
the usage of the spirometer and how to complete spirometry ac-
cording to the guidelines. The lung function reference values 
compiled by Braendli et al.  [16]  were used in the Swiss manage-
ment cohort. The ERS-ECCS reference equation as programmed 
into the EasyOne device was used as reference value in the ICE 
COLD ERIC. In both studies, all-cause mortality within 2 years 
was ascertained during follow-up assessments and confirmed by 
the GPs.
 Statistical Analysis 
 We followed a standard approach for an external out-of-pop-
ulation validation of a prediction model. We first calculated the 
2-year risk of all-cause mortality for each patient using the regres-
sion equation published recently  [6] . We then assessed discrimi-
nation by calculating the area under the curve (AUC). For calibra-
tion, we adjusted the intercept for the primary populations stud-
ied here because we looked at 2-year mortality where the 
mortality rate is expected to be lower than the 3-year mortality 
rate predicted by the ADO model. We then assessed calibration 
by comparing the predicted and observed 2-year all-cause mortal-
ity across all patients (calibration at large) and for deciles of the 
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risk distribution (i.e. 10 groups). We inspected the calibration 
plots visually and used the Hosmer-Lemeshow statistic to formal-
ly compare predicted and observed risks. We calculated the ADO 
score as recently published (from 0 to 14) for each patient. We 
used a logistic regression model with 2-year all-cause mortality as 
the dependent variable and the ADO score as the independent 
variable to compare the association [expressed as an odds ratio 
(OR)] and the AUC of the receiver-operating characteristic (ROC) 
with those observed in the large-scale ADO validation (OR 1.48 
and AUC 0.82)  [6] . We performed all analyses using STATA for 
Windows (v11.2).
 Results 
 The Swiss COPD cohort consisted of 237 patients 
( fig.  1 ) and there were 409 in the ICE COLD ERIC 
(Dutch arm: 258 and Swiss arm: 151;  fig. 2 ). In total, 646 
subjects were included in our analysis. The baseline 
characteristics are shown in  table 1 . On average, patients 
were 67.4 years old. In the Swiss cohort and the Swiss 
arm of the ICE cohort, approximately 70% were men. 
225 GPs in 23 cantons were invited
139 agreed to participate
615 patients were recruited
206 were lost to follow-up
409 patients
17 missing data 237 COPD 155 no COPD
237 COPD patients
17 deaths
220 patients (after 2 years)
409 patients (at baseline)
372 patients (after 2 years)
258 Dutch COPD patients
218 Dutch COPD patients
151 Swiss COPD patients
137 Swiss COPD patients
death
psychiatric reasons
worsening physical condition
due to inconvenience/overburden
unable to be reached/located
other reasons
proxies made further participation impossible
–23
–1
–4
–4
–1
–7
0
–12
0
0
–1
0
0
–1
 Fig. 1. Flow chart of the Swiss management COPD cohort.  Fig. 2. Flow chart of the ICE COLD ERIC. 
 Table 1.  Patients’ baseline characteristics
Swiss COPD cohort
(n = 237)
ICE COLD ERIC (n =  409) Pooled
cohort
(n = 646)
Dutch arm
(n = 258)
Swiss arm 
(n = 151)
Age, years 67.6 ± 10.8 66.4 ± 10.3 67.4 ± 9.3 67.4 ± 10.3
Male 165 (69.6) 130 (50) 103 (68.2) 398 (61.6)
Current smokers 100 (42.7) 104 (40) 53 (35.1) 257 (39.8)
BMI 25.8 ± 4.9 26.2 ± 5.4 26.2 ± 4.7 26 ± 5.1
FEV1, % 51.4 ± 19.1 55.4 ± 15.8 55.7 ± 18.0 52.4 ± 26
MMRC dyspnoea scale 1.4 ± 1.3 2.3 ± 1.6 1.1 ± 0.9 1.7 ± 1.4
Diabetes mellitus 21 (10.5) 43 (16.5) 20 (13.3) 99 (15.3)
Coronary heart disease or heart failure 43 (21.4) 53 (20.5) 25 (16.5) 121 (18.7)
Cerebrovascular accident 6 (3) 23 (9) 13 (9) 42 (6.5)
Values are mean ± SD or n (%).
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Men made up 50% of the Dutch arm of the ICE cohort. 
The cohorts were similar in terms of patients’ age, BMI 
and the frequency of comorbidities. The BMI average in 
the Swiss cohort was 25.8, which approximates the ob-
served mean BMI in both ICE cohort arms, i.e. 26.2. 
Cardiovascular disease and diabetes were common in 
both cohorts. The Dutch part of the ICE cohort had 
higher mMRC scores than the Swiss part and the Swiss 
COPD cohort. The Swiss cohort included patients with 
greater airflow obstruction than that observed in the 
ICE cohort. There were no patients with COPD GOLD 
stage I in the ICE cohort ( table 2 ); the majority had a 
moderate COPD stage, i.e. GOLD II (Dutch arm: 67% 
and Swiss arm: 63%). The Swiss cohort included COPD 
patients with mild to very severe airway obstruction 
(moderate COPD: 42.9% and severe/very severe COPD: 
54.4%). GOLD stage I prevalence was 2.5% in the Swiss 
cohort. Mean mMRC was 1.4 in the Swiss cohort, and 
1.1 and 2.3 in the Swiss and Dutch arms of the ICE co-
hort, respectively.
 During the 2-year follow-up period, 52 (8.1%) of the 
patients observed according to the protocol died. The me-
dian ADO score was 7 (range 0–14, IQR 6–9). The OR for 
death per ADO index point increase was 1.50 [95% con-
fidence interval (CI) 1.31–1.71]. A significant association 
between predicted ADO index and the observed 2-year 
risk of death was seen. The ROC AUC was 0.78 (95% CI 
0.71–0.84;  fig. 3 ). The predictive capacity of the 2 cohorts 
was similar, with an AUC of 0.76 in the Swiss COPD co-
hort and 0.79 in the ICE COLD ERIC.
 Table 2.  Lung function
Swiss COPD cohort 
(n = 237)
 ICE COLD ERIC (n = 409) Pooled cohort
(n = 646)Dutch arm 
(n = 258)
Swiss arm
(n = 151)
GOLD I 7 (2.9) 0 0 7 (1.1)
GOLD II 101 (42.6) 173 (67.1) 95 (62.9) 369 (57.1)
GOLD III 103 (43.4) 63 (24.4) 40 (26.5) 206 (31.9)
GOLD IV 26 (11) 22 (8.5) 16 (10.6) 64 (9.9)
 Values are n (%).
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 Fig. 3. Validation of the ADO index in COPD patients treated in primary care setting. The calibration curve shows 
the predicted and the observed risks of mortality. The discrimination curve illustrates the AUC. 
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 Discussion 
 The ADO index accurately predicted 2-year all-cause 
mortality in patients with COPD treated in the primary 
care setting. Our findings raise two important points. The 
first is the fact that the ADO index performs accurately in 
patients in primary care, i.e. patients cared for by their 
GP, and the second is that this index can be used to pre-
dict mortality over a shorter time period than that for 
which it was originally developed.
 The ADO index is derived from three strong predic-
tors: age, dyspnoea and airflow obstruction; Puhan et al. 
 [5] observed that the factor most strongly associated with 
3-year mortality is age, followed by FEV 1 and dyspnoea. 
These predictors are easily obtained in primary care set-
tings, which is where the majority of COPD patients are 
diagnosed and managed.
 The ADO index is a useful multidimensional index 
that includes parameters which help us to look at the pa-
tients from more than one perspective and can be ob-
tained at a single time point. Furthermore, these param-
eters do not require historical data (e.g. the number of 
exacerbations in the past 12 months), which can be inac-
curate, particularly in elderly patients with comorbid cog-
nitive impairment. This may be particularly relevant 
when a new diagnosis of COPD is made or when a patient 
is new to the GP.
 Age is a physiological parameter featuring in many 
chronic disease indices and scales such as the Framing-
ham risk score, the APACHE (Acute Physiology and 
Chronic Health Evaluation) and the CHADS 2 score  [17–
22] . Age reflects the physiological and biological path of 
humans and their disease history. It is therefore a large 
and significant contributor to mortality risk. Comorbidi-
ties, muscle atrophy and loss as well as biological cell and 
system dysfunction all manifest with increasing age.
 Dyspnoea is one of the most hindering symptoms of 
COPD. The dyspnoea grade specifies a patient’s perspec-
tive of their disease and can be easily measured using the 
mMRC. Moreover, a previous study has shown that the 
mMRC dyspnoea scale provides a better prediction of 
mortality than FEV 1  [23] .
 Lung function, expressed by FEV 1 , was the most com-
monly used prognostic factor in COPD before the devel-
opment of multi-dimensional prognosis indices such as 
the BODE, modified BODE and ADO index. Although 
FEV 1 is widely used as a predictor for mortality and a 
marker for disease development, it does not reflect a pa-
tient’s illness symptoms and does not correlate accurate-
ly with the subjective illness progress, affliction or quality 
of life  [24] . Moreover, there is a poor association between 
the degree of dyspnoea and FEV 1 , which indicates that a 
low FEV 1 does not mean a high grade of dyspnoea  [24, 
25] . We believe that multidimensional indices such as 
ADO or BODE could help to better manage COPD pa-
tients individually according to their own risk profile, and 
may help their GPs to develop new strategies for better 
treatment, rehabilitation and quality of life  [26, 27] . In-
dex-guided treatment algorithms, however, still require 
prospective evaluation in randomised controlled trials.
 The ADO index has a very good 2-year mortality pre-
diction. In COPD, there are patients who are at a higher 
risk of death than others within the next 2 years, and such 
patients can be identified by their ADO score. Poor lung 
function, especially a fast decline in lung function, is an 
important predictor for mortality in COPD  [3, 28] . Our 
data show that a GP can even estimate a patient’s 2-year 
mortality with the ADO index. Therefore, after having 
determined a patient’s ADO index score, the GPs should 
be encouraged to reassess their current treatment. In par-
ticular, those patients who have had a greater risk of mor-
tality predicted might indeed benefit from extended, 
guidelines-based treatment including pharmacological 
and non-pharmacological interventions  [8, 12, 29] .
 The purpose of the ADO index is not to reflect the 
severity of respiratory disease. Predictive models gener-
ally try to estimate the probability of an event as accu-
rately as possible but do not aim to establish a causal 
relationship or directly inform what preventive or ther-
apeutic actions to take. ADO’s purpose is to predict the 
probability that a COPD patient of a certain age with 
dyspnoea and a high level of airway obstruction will be 
dead before 2 (or 3) years have passed and to then use 
this probability to support a (shared) treatment deci-
sion, given that good evidence exists for a (fixed propor-
tional, i.e. a relative risk reduction) treatment effect on, 
in this case, mortality.
 Cardiovascular risk models such as the Framingham 
model  [17] also follow the approach that we took (for 
ADO), commonly including non-modifiable predictors 
(e.g. age, sex and sometimes familial history) because 
these substantially improve the prediction. Sometimes 
prediction models include modifiable factors that add to 
the prediction but the modification of which may not in-
fluence the outcome to any extent that is of interest. We 
think that the purpose of risk prediction and what type of 
treatment should be given can be two separate issues, as 
long as there is good evidence that the probability of death 
within 2 years can be reduced and assuming that this re-
duction is worthwhile, i.e. over a threshold that takes into 
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account adverse effects and costs, as is the case with the 
Framingham and other similar cardiovascular disease 
models.
 In COPD, treatment that improves a patient’s progno-
sis may include smoking cessation, pulmonary rehabilita-
tion or the administration of drugs or long-term oxygen 
to reduce the risk of exacerbations (and subsequently 
death). Thus, a prediction model such as ADO simply 
alerts physicians that a patient is at an increased risk of 
death. However, the steps then taken do not need to be 
restricted to modifying the predictors of the ADO index.
 A strength of our study is the inclusion of 3 groups of 
patients from 2 countries. These 3 groups were compa-
rable as well as being similar to other COPD cohorts de-
scribed in the literature, in terms of age and comorbidi-
ties. They reflect the population of COPD patients who 
are treated in primary-care settings  [30] . As expected, we 
had fewer patients with COPD stage IV than cohorts 
from more specialized settings  [3] . A potential limitation 
is that the Swiss cohort and the ICE COLD ERIC had dif-
ferent study protocols, but, given the simplicity of the 
data required for the ADO index and the all-cause mor-
tality results at 2 years, we do not think that this had an 
important influence on our analysis. Furthermore, the 
predictive capacity of the ADO index was comparable in 
both cohorts, evident from the fact that they had a very 
similar AUC.
 In conclusion, the ADO index is an accurate predictor 
of 2-year mortality in patients with COPD treated in pri-
mary care settings. The ADO index predictors can be eas-
ily obtained in general practices, which is where the ma-
jority of COPD patients are managed.
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